Novartis AG
NVS Real Time Price USD$NVS is featured in our Tom Carper and Shelley Moore Capito strategies.
All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: Peptides and compositions for treatment of joint damage Jan. 16, 2018
-
Patent Title: Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Jan. 16, 2018
-
Patent Title: Methods for preparing squalene Jan. 16, 2018
-
Patent Title: Use of somatostatin analogs in control of hypoglycemia Jan. 16, 2018
-
Patent Title: Pharmaceutical combination comprising binimetinib Jan. 16, 2018
-
Patent Title: Method of treating atherosclerosis in high triglyceride subjects Jan. 16, 2018
-
Patent Title: Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices Jan. 09, 2018
-
Patent Title: Method for characterizing an ophthalmic lens Jan. 09, 2018
-
Patent Title: Compositions and methods for antibodies targeting bmp6 Jan. 09, 2018
-
Patent Title: Polyomavirus neutralizing antibodies Jan. 09, 2018
-
Patent Title: Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Jan. 09, 2018
-
Patent Title: Intraocular lens surgical system and method Jan. 09, 2018
-
Patent Title: Mechanical support of an indirect contact lens by a surgical microscope during vitreoretinal surgery Jan. 02, 2018
-
Patent Title: Method and apparatus for determining the presence of an electrical charge on the surface of a lens mold Dec. 26, 2017
-
Patent Title: Biomarkers associated with brm inhibition Dec. 26, 2017
-
Patent Title: Method for avoiding entrapment of air bubbles in a lens forming material and apparatus for carrying out the method Dec. 26, 2017
-
Patent Title: Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists Dec. 26, 2017
-
Patent Title: Ophthalmic surgical system with moveable light filter Dec. 26, 2017
-
Patent Title: Metal oxide dispersion and uses thereof Dec. 19, 2017
-
Patent Title: Tetracyclic pyridone compounds as antivirals Dec. 19, 2017
-
Patent Title: Protein kinase c inhibitors and methods of their use Dec. 19, 2017
-
Patent Title: Internal shunt and method for treating glaucoma Dec. 19, 2017
-
Patent Title: Enhanced ophthalmic surgical experience using a virtual reality head-mounted display Dec. 19, 2017
-
Patent Title: Optical coherence tomography guided epiretinal membrane peeling Dec. 19, 2017
-
Patent Title: Devices, systems, and methods for calibrating an oct imaging system in a laser surgical system Dec. 19, 2017
-
Patent Title: Increased depth of field microscope and associated devices, systems, and methods Dec. 19, 2017
-
Patent Title: Nucleic acids and proteins from Dec. 12, 2017
-
Patent Title: Process for the manufacture of cyclic undecapeptides Dec. 12, 2017
-
Patent Title: Substituted quinazolin-4-one derivatives Dec. 12, 2017
-
Patent Title: Apparatus and method for transporting contact lenses through dipping baths Dec. 12, 2017
-
Patent Title: Intraocular pressure sensing systems, devices, and methods Dec. 12, 2017
-
Patent Title: Transformer irrigation/aspiration device Dec. 12, 2017
-
Patent Title: Graphical user interface system and method for representing and controlling surgical parameters Dec. 12, 2017
-
Patent Title: Contact lens packaging solutions Nov. 28, 2017
-
Patent Title: Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment Nov. 28, 2017
-
Patent Title: Nucleic acids encoding silent fc variants of anti-cd40 antibodies Nov. 28, 2017
-
Patent Title: Method for testing a laser device Nov. 28, 2017
-
Patent Title: Systems and techniques for tissue manipulation during ocular surgery Nov. 28, 2017
-
Patent Title: Methods and systems for pulsed illumination Nov. 28, 2017
-
Patent Title: Surgical microscope with integrated optical coherence tomography and display systems Nov. 28, 2017
-
Patent Title: Method for detecting the presence or absence of an ophthalmic lens, in particular a contact lens, within a receptacle Nov. 21, 2017
-
Patent Title: Arylsulfonamide-based matrix metalloprotease inhibitors Nov. 21, 2017
-
Patent Title: Silicone hydrogel lenses with water-rich surfaces Nov. 14, 2017
-
Patent Title: Treatment of cancer using a cd123 chimeric antigen receptor Nov. 14, 2017
-
Patent Title: Antibody molecules to pd-1 and uses thereof Nov. 14, 2017
-
Patent Title: Pyrazolo pyrimidine derivatives and their use as malt1 inhibitors Nov. 14, 2017
-
Patent Title: Complement pathway modulators and uses thereof Nov. 14, 2017
-
Patent Title: 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of shp2 Nov. 14, 2017
-
Patent Title: Isoxazole hydroxamic acid compounds as lpxc inhibitors Nov. 14, 2017
-
Patent Title: 2′-ethynyl nucleoside derivatives for treatment of viral infections Nov. 14, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.